Effects of dapagliflozin on urinary output, fluid balance, and biochemistry in critically ill patients: a post-hoc secondary analysis of the DEFENDER trial
Authors' conclusion
This exploratory analysis suggests dapagliflozin may enhance diuresis and reduce loop diuretic requirements in critically ill patients, potentially at the cost of increased vasopressor needs.
Study context
- Population
- Critically ill patients with acute organ dysfunction
- Participants
- 401 patients
- Comparison
- Dapagliflozin 10 mg daily vs standard care
Methodological detailspost-hoc, Bayesian models, exploratory
- Post-hoc
- Bayesian models
- Exploratory
Primary result
As reported in the abstract
Urinary output and fluid balance (dapagliflozin vs standard care) · day 5
Dapagliflozin vs Standard careDifference in fluid balance, mL/day (95% CrI)
CrI; probability 98%
−290(−564 to −27)
- CrI; probability 90%
- difference in urinary output + 157 mL/day (95% CrI −90 to 386)
Further findings
| Outcome | Difference (95% CrI) | |
|---|---|---|
| Furosemide useOverall; CrI; probability 90% | −3% (−7% to 1%) | |
| −10−505Difference (linear scale) |
| Outcome | Estimate |
|---|---|
| pH · day 5Probability 96%; progressive small decreases | difference −0.02 |
| Maximum glucoseOverall; probability 83% | difference −9 mg/dL |
Creatinine and electrolytes
- Minimal effects of dapagliflozin
Safety
| Outcome | Expected dose difference (mcg/kg/min) |
|---|---|
| Norepinephrine requirements · day 5Probability 94%; time-dependent increase | 0.034 |
Norepinephrine requirements · day 5
- Larger effects in patients with sepsis or on mechanical ventilation (heterogeneity analysis)
Original publication
Effects of dapagliflozin on urinary output, fluid balance, and biochemistry in critically ill patients: a post-hoc secondary analysis of the DEFENDER trial. Crit Care. Published 11 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →